NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Empress Therapeutics

Empress Therapeutics

Private
Watertown, MassachusettsHealthcare & Life Scienceshttps://www.empresstx.com/

Last Round

Series A

Jun 21, 2023

Total Funding Raised

$50M

Company Overview

Empress Therapeutics is a biotechnology company that develops small-molecule drug candidates by leveraging its proprietary Chemilogics platform, which integrates genetic data, artificial intelligence, and synthetic biology to identify drug starting points from the human body.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

drug discoverysmall molecule therapeuticsinvestigational new drugINDbiotechnologygenomicscausal machine learningbiotechmulti-omicschemoproteomicsai-native biotechdrug pipelinein silico drug discoverycomputational biologypharma partnership

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Empress Therapeutics Comparables

Compare Empress Therapeutics with similar companies based on industry and business-model similarity.

Empress Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vesalius Therapeutics
86%
LifeMine Therapeutics
82%
Hexagon Bio
80%

Empress Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 21, 2023

Empress Therapeutics Investors

Notable investors and investment history

Empress Therapeutics investors
InvestorRounds
Flagship PioneeringSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 21, 2023

    $50M round led by Flagship Pioneering

Empress Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Empress Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Empress Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWatertown, Massachusetts
Employee Range16
Year Founded2020
Last FundingJun 21, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.